- Explore the mechanism of action and preclinical efficacy of a first-in-class oncolytic peptide targeting triple negative breast cancer (TNBC).
- Understand how peptide-based approaches offer new hope for aggressive and treatment-refractory subtypes of breast cancer.
- Learn about the breast cancer therapeutic roadmap and landscape.
Session Topics:
Oncology
Speaker(s):
Mark Eccleston
Chief Executive Officer
ValiRx
Session Job Focus:
Time:
3:30 PM - 4:00 PM
Agenda Track No.:
Track 7
Session Type:
Track